Bachem Holding (BANB) Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BANB Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 68.05 |
| 52 Week High | CHF 76.00 |
| 52 Week Low | CHF 48.20 |
| Beta | 0.79 |
| 1 Month Change | 7.17% |
| 3 Month Change | -4.22% |
| 1 Year Change | 35.15% |
| 3 Year Change | -29.19% |
| 5 Year Change | -25.87% |
| Change since IPO | 386.07% |
Recent News & Updates
Recent updates
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
Dec 01
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Oct 25Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
Aug 16Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
Jul 30Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Jul 25Bachem Holding AG's (VTX:BANB) Share Price Matching Investor Opinion
May 15
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Shareholder Returns
| BANB | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -0.9% | -5.8% | -0.6% |
| 1Y | 35.2% | -15.0% | 7.3% |
Return vs Industry: BANB exceeded the Swiss Life Sciences industry which returned -13.6% over the past year.
Return vs Market: BANB exceeded the Swiss Market which returned 8.8% over the past year.
Price Volatility
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 8.3% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: BANB's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: BANB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANB fundamental statistics | |
|---|---|
| Market cap | CHF 5.10b |
| Earnings (TTM) | CHF 148.79m |
| Revenue (TTM) | CHF 695.07m |
Is BANB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANB income statement (TTM) | |
|---|---|
| Revenue | CHF 695.07m |
| Cost of Revenue | CHF 495.34m |
| Gross Profit | CHF 199.73m |
| Other Expenses | CHF 50.94m |
| Earnings | CHF 148.79m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 1.99 |
| Gross Margin | 28.74% |
| Net Profit Margin | 21.41% |
| Debt/Equity Ratio | 3.9% |
How did BANB perform over the long term?
See historical performance and comparisonDividends
Does BANB pay a reliable dividends?
See BANB dividend history and benchmarks| Bachem Holding dividend dates | |
|---|---|
| Ex Dividend Date | May 04 2026 |
| Dividend Pay Date | May 06 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 6 days |
Does BANB pay a reliable dividends?
See BANB dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/29 23:57 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bachem Holding AG is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |